Evolus Inc., a performance beauty company, has announced the publication of a U.S. pivotal study in the Aesthetic Surgery Journal, detailing the results for its injectable hyaluronic acid gels, Evolysse™ Form and Evolysse™ Smooth. The study demonstrated that both products met the primary endpoint of non-inferiority and showed statistical superiority over the control product, Restylane®-L. The research supports the long-term safety and effectiveness of these gels for correcting dynamic facial wrinkles and folds. Evolysse™ Form achieved more correction with the same amount of product as the control, while Evolysse™ Smooth reached statistical significance at 6 and 9 months despite using 20% less product. The safety profile of both Evolysse™ products was comparable to the control, with no treatment-related serious adverse events reported. Evolus has also received EU Medical Device Regulation approval for its Estyme® brand of HA gels, with plans for a broader European launch in the second half of 2025.